Organization | Tianjin Cansino Biotechnology Inc

Tianjin Cansino Biotechnology Inc Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Tianjin China (2009)

Status: No NME R&D (2009)

Organization Overview

First Clinical Trial

2014

NCT02326194

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

CanSino Biologics Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

inactivated SARS-Cov-2 vaccine (2 trials)

sars-cov-2 ad5 (2 trials)

Drugs in Phase 3 Trials (4)

ad5-ncov (12 trials)

bivalent recombinant covid-19 vaccine (adenovirus type 5 vector) (1 trial)

bnt162b2 (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

Drugs in Phase 2 Trials (2)

ebola vaccine (1 trial)

recombinant novel coronavirus vaccine (adenovirus type 5 vector) (1 trial)

Drugs in Phase 1 Trials (7)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

ad5-ebov (3 trials)

dt polio (1 trial)

haemophilus influenzae type b conjugate vaccine (PedvaxHIB) (1 trial)

Protein Based Pneumococcal Vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenoviridae Infections (Phase 2)

Communicable Diseases (Phase 1)

Coronavirus Infections (Phase 3)

Diphtheria (Phase 1)

Hemorrhagic Fever, Ebola (Phase 2)

Infections (Phase 1)

Pneumococcal Infections (Phase 1)

Pneumonia (Phase 1)

Respiratory Tract Diseases (Phase 1)

Respiratory Tract Infections (Phase 1)

Streptococcal Infections (Phase 1)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 24
# of Trial APIs: 15